18:10 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo....
12:15 , Oct 12, 2018 |  BC Extra  |  Clinical News

Phase II data for Merck's Btk inhibitor highlighted at ECTRIMS

Merck KGaA (Xetra:MRK) reported 24-week data from a Phase II trial to treat relapsing multiple sclerosis showing that evobrutinib (M2951) reduced the mean total number of gadolinium-enhancing T1 lesions by up to 2.7 over placebo....
22:56 , Oct 11, 2018 |  BC Week In Review  |  Clinical News

Reata's CKD candidate improves kidney function in IgA nephropathy, diabetes cohorts

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported data from the IgA nephropathy and chronic kidney disease (CKD) associated with Type I diabetes cohorts of the open-label, U.S. Phase II PHOENIX trial of bardoxolone methyl to treat rare...
15:38 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Reata reports retained benefit in Phase II CKD trial

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported Phase II data showing that chronic kidney disease (CKD) patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR) four weeks after discontinuing treatment. In 25...
22:30 , Jul 23, 2018 |  BC Extra  |  Clinical News

Reata gains on retained benefit in CKD trial, proposes follow-on

Reata Pharmaceuticals Inc. (NASDAQ:RETA) added $30.15 (65%) to $76.55 on Monday after reporting Phase II data showing that chronic kidney disease patients who received bardoxolone methyl retained their improvements in estimated glomerular filtration rate (eGFR)...
19:05 , Jun 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies suggest activating NFE2L2 could help treat ALS by promoting normal folding of mutant SOD1. Crystallographic analyses of an ALS-associated SOD1 mutant complexed with a library of cysteine-reactive...
17:17 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Reata reports Phase II data for omaveloxolone in mitochondrial myopathies

Reata Pharmaceuticals Inc. (NASDAQ:RETA) reported top-line data from the Phase II MOTOR trial in 53 patients with mitochondrial myopathies showing that omaveloxolone (oral RTA 408) missed the primary endpoint of improving peak workload during exercise...
21:34 , Feb 28, 2018 |  BC Extra  |  Financial News

Celgene's slide continues after refusal to file letter

Celgene Corp. (NASDAQ:CELG) shed $8.66 to $87.12 on Wednesday after FDA issued a refusal to file letter for an NDA for ozanimod (RPC1063) to treat multiple sclerosis. The news was announced after market close Tuesday...
20:26 , Feb 2, 2018 |  BC Week In Review  |  Company News

EPO revokes Forward patent related to Tecfidera

Forward Pharma A/S (NASDAQ:FWP) said the European Patent Office revoked Forward's European Patent No. EP2801355, which Forward claims is infringed by blockbuster multiple sclerosis drug Tecfidera dimethyl fumarate from Biogen Inc. (NASDAQ:BIIB). The company told...
23:36 , Jan 29, 2018 |  BC Extra  |  Company News

EPO revokes Forward patent related to Tecfidera

Forward Pharma A/S (NASDAQ:FWP) lost $1.49 (28%) to $3.87 on Monday after the European Patent Office revoked Forward's European Patent No. EP2801355, which Forward claims is infringed by blockbuster multiple sclerosis drug Tecfidera dimethyl fumarate...